A federal judge in California refused to allow class action certification in a lawsuit against GlaxoSmithKline regarding Paxil (paroxetine hydrochloride)."Paxil is an important medicine in the lives of millions of patients, and we continue to stand firmly behind its safety and efficacy," said Chris Viehbacher, president of US Pharmaceuticals, GSK. "We welcome the judge's decision on this motion."

The judge said the plaintiffs failed to meet the requirements for class certification. While the plaintiffs have the opportunity to try to address the defects in their case by submitting one more motion, Judge Mariana R. Pfaelzer wrote in her ruling that, "Additionally, while the substance of any motion is ultimately determined by the filing party, the Court has grave doubts about the viability of any multi-state class action proposal."

Paxil (paroxetine hydrochloride), a selective serotonin reuptake inhibitor (SSRI), is indicated for depression and all major anxiety disorders, including social anxiety disorder, panic disorder, obsessive compulsive disorder, generalized anxiety disorder and post-traumatic stress disorder.